Neurotech International Limited (ASX: NTI), a clinical-stage biopharmaceutical company developing cannabinoid therapies for paediatric neurological disorders, has issued ordinary fully paid shares without disclosure to investors under relief provisions of the Corporations Act. The company provided notice on 21 July 2026 confirming compliance with Chapter 2M of the Act and related provisions. The notice relates to shares detailed in an Appendix 2A released on the same date.
Key Points
- Neurotech International Limited (ASX: NTI) is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders
- The company issued ordinary fully paid shares under section 708A(5)(e) of the Corporations Act 2001 (Cth) on 21 July 2026
- Shares were issued without disclosure to investors under Part 6D.2 of the Act, using available relief provisions
- The company confirmed compliance with Chapter 2M and sections 674 and 674A of the Corporations Act as at the notice date
- No excluded information as defined under section 708A(7) of the Corporations Act was identified
- The company's lead candidate NTI164 has completed Phase II/III trials in Autism Spectrum Disorder with statistically significant results
Neurotech's Lead Cannabinoid Therapy NTI164 and Clinical Development Program
Neurotech International Limited is a clinical-stage biopharmaceutical development company with a focus on developing therapies for paediatric neurological disorders. The company's primary asset is NTI164, a broad-spectrum oral cannabinoid drug therapy that has undergone multiple clinical trials across several neurological conditions affecting children and young people. The company announced that NTI164 has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD), with results showing clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and demonstrated excellent safety.
Beyond the ASD program, Neurotech has advanced its development pipeline in additional paediatric neurological indications. The company completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively referred to as PANDAS/PANS, along with Rett Syndrome. These completed trial results demonstrate the broad applicability of the NTI164 platform across multiple rare and serious paediatric neurological conditions. The company has also received human ethics committee clearance for a Phase III Clinical Study in ASD, signalling progression toward later-stage clinical development in its lead indication.
Share Issuance Under Section 708A Relief Provisions of the Corporations Act
Neurotech International has issued ordinary fully paid shares in the capital of the company without providing disclosure documentation to investors. This share issuance was conducted under the relief provisions contained in section 708A(5)(e) of the Corporations Act 2001 (Cth), and the shares were issued without disclosure to investors under Part 6D.2 of the Act. The specific details of the share issuance, including the number of shares issued and the consideration received, were referenced in an Appendix 2A released by the company on 21 July 2026, the same date as this secondary trading notice.
The use of section 708A relief provisions allows certain companies to issue securities without the requirement to prepare a disclosure document, subject to specified compliance conditions being met. Neurotech's reliance on this mechanism suggests the company has satisfied the statutory requirements and conditions necessary to access this exemption from the disclosure obligations that would otherwise apply under Part 6D.2 of the Corporations Act. The company's announcement of this transaction through a secondary trading notice is consistent with regulatory obligations to inform the market of capital management activities, even where the full disclosure regime does not apply to the original issuance.
Regulatory Compliance Confirmations and Excluded Information Assessment
The company provided explicit confirmations regarding its compliance status as at the date of the notice. Neurotech confirmed that it has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the company, and has also complied with sections 674 and 674A of the Corporations Act. Chapter 2M contains provisions relating to financial reporting and disclosure obligations, while sections 674 and 674A set out requirements for the lodgement of constitutional documents and other corporate governance matters. These confirmations are material to the validity and propriety of the share issuance conducted under the section 708A relief provisions.
Additionally, the company made an assessment of whether any information that would constitute "excluded information" as defined in section 708A(7) of the Corporations Act existed as at the date of the notice. The company advised that there is no information to be disclosed which is excluded information that is reasonable for investors and their professional advisers to expect to find in a disclosure document. This assessment is significant because the presence of excluded information would have precluded reliance on the section 708A relief, thereby requiring preparation and lodgement of a disclosure document prior to the issuance of the shares. The absence of such information supports the propriety of the company's reliance on the statutory relief available under section 708A(5)(e).
Neurotech's Focus on Paediatric Neurological Disorders and Unmet Clinical Needs
Neurotech International has positioned itself in a specialised segment of the biopharmaceutical industry, targeting paediatric neurological disorders where substantial unmet clinical needs exist. Autism Spectrum Disorder, one of the company's primary clinical focus areas, affects a significant proportion of the paediatric population globally and currently lacks disease-modifying treatment options. The successful completion of Phase II/III trials in ASD with statistically significant and clinically meaningful results represents substantial progress in addressing this unmet need, and the receipt of ethics clearance for Phase III studies indicates the company's pathway toward potential regulatory submission.
PANDAS and PANS represent additional specialised paediatric neurological conditions with significant unmet medical needs and limited treatment options available to affected patients and their families. Rett Syndrome is a rare but severe neurological disorder affecting primarily female infants and young children. By developing a single therapeutic platform (NTI164) with potential efficacy across multiple paediatric neurological indications, Neurotech is pursuing a strategy that could address several distinct patient populations with a common mechanism of action. The cannabinoid modulation approach represents a differentiated mechanism within the paediatric neurological space and may offer advantages in terms of safety, tolerability, and efficacy compared to existing treatment paradigms.
Implications of Share Issuance for Capital Structure and Future Funding
The issuance of ordinary fully paid shares represents a capital management transaction that will have altered the company's capital structure and equity base. While the announcement does not disclose the number of shares issued or the valuation at which they were issued, the transaction was undertaken in accordance with statutory relief provisions, suggesting it was structured to meet the requirements of the regulatory framework. The use of the secondary trading notice mechanism indicates the company sought to provide transparency to the market regarding the capital transaction, consistent with ASX listing rules requirements even where the full disclosure regime did not apply.
For investors, the share issuance may have implications for share ownership percentage and earnings per share calculations going forward. The company did not disclose specific details regarding the number of shares issued, the total consideration received, or the identity or investment rationale of the recipients. These details would typically be found in the referenced Appendix 2A document released on the same date. The capital raised through this issuance may be deployed toward advancement of the company's clinical development programs, including the Phase III ASD trial and other development initiatives, or toward general corporate purposes and working capital requirements.
Clinical Trial Efficacy Data and Therapeutic Potential of NTI164
The completion of the Phase II/III randomised, double-blind, placebo-controlled trial in Autism Spectrum Disorder with reported clinically meaningful and statistically significant benefits across multiple clinically-validated measures represents a significant milestone in the company's development program. The fact that the trial was designed as a Phase II/III combined trial suggests the company and its regulatory advisers had determined that sufficient preliminary efficacy and safety data existed to justify progressing directly to a pivotal efficacy trial rather than conducting separate Phase II and Phase III studies. The reported results indicating clinically meaningful as well as statistically significant benefits suggest the magnitude of benefit observed was not only statistically significant but also clinically relevant to patients and their families.
The reported excellent safety profile of NTI164 in the ASD trial is particularly noteworthy given that the drug is a cannabinoid-based therapy being developed for paediatric populations. Safety in the paediatric setting is of paramount importance to regulatory authorities, healthcare providers, and parents. The successful demonstration of both efficacy and safety in the Phase II/III trial provides a substantial foundation for the company's Phase III development program. The receipt of human ethics committee clearance for the Phase III ASD trial indicates that regulatory and ethics oversight bodies have accepted the trial design and safety assessment, clearing the pathway for the company to initiate and enrol patients in this pivotal study.
Competitive Landscape and Market Position in Paediatric Neurological Therapeutics
Neurotech International operates in the biopharmaceutical sector, specifically in the paediatric neurological therapeutics space, which is characterised by high barriers to entry, substantial regulatory requirements, and significant capital intensity. The development of new therapies for paediatric neurological disorders requires extensive clinical trial programs, regulatory navigation, and post-approval pharmacovigilance and monitoring. Competition in this space comes from both large pharmaceutical companies with established paediatric development capabilities and smaller biopharmaceutical companies pursuing novel approaches. The company's focus on a cannabinoid-based platform for multiple paediatric neurological indications represents a differentiated approach within this competitive environment.
Neurotech's current position as a clinical-stage company with Phase II/III trial results in ASD and completed Phase I/II trials in multiple indications places it at an intermediate stage of development relative to early-stage discovery companies and commercial-stage companies with approved products. The completion of substantial clinical development work and the advancement toward Phase III trials provide the company with potential competitive advantages in terms of clinical data, regulatory momentum, and intellectual property positioning. However, the company remains subject to the inherent risks and uncertainties of drug development, including regulatory review outcomes, competitive responses, intellectual property challenges, and manufacturing and commercialisation hurdles that would need to be overcome to achieve commercial success.
Regulatory Path Forward and Next Clinical Milestones
With human ethics committee clearance obtained for the Phase III ASD trial, the company's next major clinical milestone is the initiation and conduct of this pivotal efficacy and safety study. Phase III trials are typically large, multi-centre, prospective studies designed to confirm the efficacy of a therapeutic intervention in the intended patient population and to monitor adverse reactions and other safety outcomes. The successful completion of the Phase III ASD trial and demonstration of consistent efficacy and safety would typically support a regulatory submission to relevant therapeutic goods agencies, such as the Therapeutic Goods Administration in Australia or equivalent regulatory authorities in other jurisdictions where the company may seek approval.
The regulatory pathway for cannabinoid-based therapeutics in the paediatric setting is evolving, as regulatory authorities develop experience with cannabis-derived medicines and gain experience with their use in rare neurological conditions. Neurotech's engagement with ethics committees and regulatory bodies through its clinical development program provides opportunities to build regulatory understanding of NTI164's profile and to establish confidence in the therapeutic benefit-risk relationship. The company's focus on statistically significant and clinically meaningful efficacy, coupled with demonstrated excellent safety, positions the company well for regulatory discussions regarding the risk-benefit profile of the compound in these paediatric populations.
Risks Related to Paediatric Drug Development and Regulatory Approval
Neurotech International faces inherent risks associated with the development of pharmaceuticals for paediatric populations. Paediatric drug development requires particularly rigorous safety assessments, as regulatory authorities and ethics committees apply heightened scrutiny to ensure that risks are minimised and that potential benefits justify any exposures to children. The population-specific factors associated with paediatric patients, including developmental considerations, variable pharmacokinetics and pharmacodynamics across different age groups, and age-related differences in adverse event manifestation, create complexity in trial design and interpretation. Regulatory requirements for paediatric drug development may mandate additional studies, extended monitoring periods, or specific safety assessments that increase development timelines and costs.
The company's reliance on cannabinoid-based therapeutics creates a specific regulatory and commercial risk, as cannabinoid medicines remain subject to evolving regulatory frameworks and shifting policy environments in different jurisdictions. Political and regulatory attitudes toward cannabis-based medicines vary substantially across countries and regions, and changes in regulatory status or policy could affect the company's ability to develop, approve, or commercialise NTI164 in key markets. Additionally, the paediatric neurological therapeutics space is subject to intense regulatory scrutiny regarding efficacy standards and safety requirements, and regulatory authorities may impose requirements that the company has not anticipated or may decline to approve the drug based on safety or efficacy concerns that emerge during trial conduct or review.





_11_18_2026_12_41_48_650646.jpg)
Please wait processing your request...